沙库巴曲缬沙坦在心力衰竭及合并其他疾病中的应用进展

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (423 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The drug treatment of chronic heart failure has changed from strengthening heart, diuresis and vasodilation to inhibiting neuroendocrine. As a new generation of neuroendocrine inhibitor, Sacubitril Valsartan has been paid more and more attention in recent years. It has been found that its efficacy is not only limited to patients with heart failure with reduced ejection fraction (HFrEF), but also benefit patients with non-HFrEF. In addition, existing studies have shown that Sacubitril Valsartan shows superiority in heart failure complicated with other diseases. This paper reviews the efficacy of Sacubitril Valsartan in the treatment of non-HFrEF and heart failure complicated with other diseases,and looks forward to the application of Sacubitril Valsartan in a wider population.

Key words： Sacubitril Valsartan Heart failure Neprilysin Hypertension Diabetes mellitus Chronic kidney disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Min1
	ZHAO Zuqin1
	ZHONG Xuanming1
	SHI Jiaqi1
	LIU Zhida1
	LI Xuefeng2

Cite this article:

FANG Min1,ZHAO Zuqin1,ZHONG Xuanming1, et al. Application progress of Sacubitril Valsartan in heart failure and other diseases[J]. 中国当代医药, 2022, 29(9): 32-36.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I9/32

[1]	Ponikowski P, Voors AA,Anker SD, et al.2016 ESC Guide-lines for the diagnosis and treatment of acute and chronicheart failure:The Task Force for the diagnosis and treat-ment of acute and chronic heart failure of the European So-ciety of Cardiology (ESC) Developed with the special con-tribution of the Heart Failure Association( HFA ) of theESC[J].Eur Heart J,2016,37(27):2129-2200.
[2]	中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J.中华心力衰竭和心肌病杂志,2018,2(4): 196-225.
[3]	Bayes -Genis A , Nunez J , Lupon J.Sacubitril/Valsartan asAntifibrotic Drug:Rejuvenating the Fibrosed HFpEF Heart[J].J Am Coll Cardiol, 2020,76(5):515-517.
[4]	Gori M,D'Elia E,Senni M.Sacubitrilvalsartan therapeuticstrategy in HFpEF: Clinical insights and perspectives[J].IntJCardiol,2019,281:158-165.
[5]	Salazar J , Rojas-Quintero J ,Cano C,et al.Neprilysin: A Po-tential Therapeutic 'Target of Arterial Hypertension?[JJ.CurrCardiol Rev ,2020,16(1 ):25-35.
[6]	Vardeny O,Miller R,Solomon SD.Combined neprilysin andrenin -angiotensin system inhibition for the treatment ofheart failure[J].JACC Heart Fail ,2014,2(6):663-670.[7]McMurray JJ ,Packer M,Desai AS,et al.Angiotensin-neprilysininhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[8]	Solomon SD ,McMurray JV , Anand IS,et al.Angiotensin -Neprilysin Inhibition in Heart Failure with Preserved Ejec-tion Fraction[J].N Engl J Med,2019,381 (17):1609-1620.
[9]	Moliner P, Lupon J ,Barallat J,et al.Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejec-tion fraction[J].Int J Cardiol, 2018,257:188-192.
[10]	Solomon SD , Vaduganathan M ,L Claggett B,et al.Sacubi-tril/Valsartan Across the Spectrum of Ejection Fraction inHeart Failure[JJ.Circulation,2020,141(5):352-361.
[11]	Vaduganathan M ,Jhund PS, Claggett BL,et al.A putative placebo analysis of the effects of sacubitril/valsartan inheart failure across the full range of ejection fraction[J].Eur Heart J,2020,41(25):2356-2362.
[12]	中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要叮.中国循环杂志,2020,35(9):833-854.
[13]	Wehland M,Simonsen U , Buus NH ,et al.An evaluation of the fixed -dose combination sacubitril/valsartan for thetreatment of arterial hypertension[J].Expert Opin Pharma-cother , 2020,21(10):1133-1143.
[14]	Wang 'TD,Tan RS,Lee HY ,et al.Effects of Sacubitril/Val-sartan (LCZ696) on Natriuresis , Diuresis , Blood Pres-sures ,and NT一proBNP in Salt -Sensitive Hypertension[J].Hypertension, 2017,69(1):32-41.
[15]	Supasyndh O, Wang J , Hafeez K,et al.Efficacy and Safety of Sacubitril/Valsartan(LCZ696)Compared With Olme-sartan in Elderly Asian Patients (>/=65 Years)With Sys-tolic Hypertension[J].Am J Hypertens,2017,30( 12):1163-1169.
[ 16]	Jackson AM ,Jhund PS,Anand IS,et al.Sacubitril-valsartan as a treatment for apparent resistant hypertension in patientswith heart failure and preserved ejection fraction[J].EurHeart J,2021,42(36):3741-3752.
[21]	Campbell DJ.Long-term neprilysin inhibition-implications for ARNIs[J]J.Nat Rev Cardiol, 2017,14(3):171-186.
[22]	Coue M ,Moro C.Natriuretic peptide control of energy bal-ance and glucose homeostasis[J].Biochimie, 2016,124:84-91.
[26]	王华,李莹莹,柴坷,等.中国住院心力衰竭患者流行病学及治疗现状[叮.中华心血管病杂志,2019,47( 11):865-874.
[17]	Geng Q, Yan R, Wang Z,et al.Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hyperten-sion : A Meta-Analysis of Randomized Controlled 'Trials[J].Cardiology , 2020,145(9):589-598.
[18]	Unger T, Borghi C,Charchar F,et al.2020 Intermational Society of Hypertension global hypertension practice guide-lines[J].J Hypertens,2020,38(6):982-1004.
[19]	Ali A,Bain S,Hicks D ,et al.SGLT2 Inhibitors : Cardiovas-cular Benefits Beyond HbA1c -Translating Evidence intoPractice[J].Diabetes Ther ,2019,10(5):1595-1622.
[20]	Vemes E,Ducharme A , Bourassa MG,et al.Enalapril re-duces the incidence of diabetes in patients with chronicheart failure : insight from the Studies Of Left VentricularDysfunction (SOLVD)[J].Circulation ,2003,107(9):1291-1296.
[23]	Seferovic JP , Claggett B, Seidelmann SB,et al.Effect of sacubitril/valsartan versus enalapril on glycaemic controlin patients with heart failure and diabetes : a post -hocanalysis from the PARADIGM-HF trial[J].Lancet DiabetesEndocrinol , 2017,5(5):333-340.
[24]	Jordan J ,Stinkens R,Jax T,et al.Improved Insulin Sensi-tivity With Angiotensin Receptor Neprilysin Inhibition inIndividuals With Obesity and Hypertension[J].Clin Pharma-col Ther,2017,101(2):254-263.
[25]	Feldman EL,Nave KA ,Jensen 'TS,et al.New Horizons in Di-abetic Neuropathy : Mechanisms,Bioenergetics, and Pain[J].Neuron,2017,93(6): 1296-1313.
[27]	Testani JM , Kimmel SE, Dries DL,et al.Prognostic impor-tance of early worsening renal function after initiation ofangiotensin -converting enzyme inhibitor therapy in pa-tients with cardiac dysfunction[J].Circ Heart Fail , 2011 ,4(6):685-691.
[28]	Kim HJ,Lee MH ,Jo SH,et al.Effects of Angiotensin-Con-verting Enzyme Inhibitorsand Angiotensin -ReceptorBlockers in Heart Failure With Chronic Kidney Disease-Propensity Score Matching Analysis[J].Circ J ,2019,84( 1):83-90.
[29]	Packer M, Califf RM , Konstam MA, et al.Comparison ofomapatrilat and enalapril in patients with chronic heartfailure : the Omapatrilat Versus Enalapril Randomized Trialof Utility in Reducing Events(OVERTURE)[J.Circula-tion . 2002.106(8).920-926.
[30]	Haynes R, Judge PK,Staplin N,et al.Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With ChronicKidney Disease[J].Circulation,2018,138( 15) :1505-1514.
[31]	Pontremoli R,Borghi C,Perrone Filardi P.Renal protection in chronic heart failure:focus on sacubitril/valsartan[J].EurHeart J Cardiovasc Pharmacother , 2021,7(5):445-452.